THE COMBINATION OF LOVASTATIN AND ENALAPRIL IN A MODEL OF PROGRESSIVE RENAL-DISEASE

被引:22
作者
BROUHARD, BH
TAKAMORI, H
SATOH, S
INMAN, S
CRESSMAN, M
IRWIN, K
BERKLEY, V
STOWE, N
机构
[1] Departments of Pediatrics, Research Institute, Cleveland Clinic Foundation, Cleveland, 44195, Ohio
[2] Departments of Hypertension/Nephrology, Research Institute, Cleveland Clinic Foundation, Cleveland, 44195, Ohio
[3] Departments of Cardiovascular Biology, Research Institute, Cleveland Clinic Foundation, Cleveland, 44195, Ohio
关键词
ENALAPRIL; LOVASTATIN; PUROMYCIN; RENAL FAILURE; NEPHROTIC SYNDROME;
D O I
10.1007/BF00856524
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Puromycin-induced nephrotic syndrome is an animal model of progressive renal disease. Both angiotensin converting enzyme inhibitors and lipid-lowering agents have been used to preserve renal structure and function in this model, although neither completely prevents progression. We tested the hypothesis that the combination of the two agents would be more protective than either alone. Rats were divided into five groups; all were uninephrectomized. Four groups were given puromycin at a dose of 10 mg/100 g body weight (BW) with additional doses of 4 mg/100 g BW given intraperitoneally at 4, 5, and 6 weeks thereafter. One group was given enalapril (EN) 50 mg/l dissolved in the drinking water; the second received lovastatin (L) 15 mg/kg given daily by gavage; the third received both agents; the fourth was left untreated, and the final group received no puromycin and served as the control group. Eight weeks after the initial dose of puromycin, glomerular filtration rate (GFR), as inulin clearance, and protein excretion were determined and blood was collected for cholesterol and triglycerides. Blood pressure was not different between any of the groups. At the end of the study period, serum cholesterol [mean +/- SD, 252 +/- 185 mg/dl (L), 135 +/- 101 mg/dl (L + EN)] and triglycerides (239 +/- 200, 148 +/- 158 mg/dl) were significantly lower (P < 0.001) in the lovastatin-treated groups than in the untreated puromycin group (535 +/- 255 mg/dl and 579 +/- 561 mg/dl, cholesterol and triglyceride, respectively). Likewise protein excretion was significantly lower (P < 0.001) in these groups also [507 +/- 336 (L), 253 +/- 331 (L + EN) vs. 745 +/- 381 (puromycin) mg/24 h]. Renal function was also preserved with a significantly better GFR per gram kidney weight in the lovastatin-treated groups [0.56 +/- 0.33 (L), 0.54 +/- 0.19 (L + EN) vs. 0.17 +/- 0.11 ml/min per gram]. Glomerulosclerosis, as measured by a sclerotic index, was also significantly less in the lovastatin plus enalapril-treated group (0.29 +/- 0.35) compared with the untreated puromycin group (2.29 +/- 0.54). Although enalapril had little effect by itself, the combination of enalapril and lovastatin appeared to significantly improve the decrease in serum cholesterol, triglyceride, and protein excretion. Thus treatment with lovastatin alone, and its subsequent lowering of serum cholesterol and triglyceride concentrations, improved renal structure and function in this model of puromycin nephrosis. The combination of lovastatin and enalapril resulted in the least histological damage, the least protein excretion, and preservation of GFR,
引用
收藏
页码:436 / 440
页数:5
相关论文
共 23 条
  • [11] Raji L., Azar S., Keasne W.F., Mesangial immune injury, hypertension and progressive glomerular damage in Dahl rats, Kidney International, 26, pp. 137-143, (1984)
  • [12] Smith H., Principles of renal physiology, pp. 196-215, (1965)
  • [13] Diamond J.R., Karnovsky M.J., Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside, Am J Pathol, 122, pp. 481-487, (1986)
  • [14] Grond J., Weening J.J., Elema J.D., Glomerular sclerosis in nephrotic rats, Lab Invest, 51, pp. 277-285, (1984)
  • [15] Kasiske B.L., O'Donnell M.P., Garvis W.J., Keane W.F., Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure, Circ Res, 62, pp. 367-374, (1988)
  • [16] Marinides G.N., Groggel G.C., Cohen A.H., Cook T., Baranowski R.L., Westenfelder C., Border W.A., Failure of angiotesin converting enzyme inhibition to affect the course of chronic puromycin aminonucleoside nephropathy, Am J Pathol, 129, pp. 394-401, (1987)
  • [17] Marinides G.N., Groggel G.C., Cohen A.H., Border W.A., Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy, Kidney International, 37, pp. 749-757, (1990)
  • [18] Trachtman H., Zavilowitz B., Bennett B., Goldsmith D.I., The effect of captopril on urinary protein excretion in puromycin aminonucleoside nephrosis in rats, Pediatr Res, 19, pp. 823-834, (1985)
  • [19] Trachtman H., Del Pizzo R., Valderrama E., Gauthier B., The renal functional and structural consequences of corticosteroid and angiotensin-converting enzyme inhibitor therapy in chronic puromycin aminonucleoside nephropathy, Pediatr Nephrol, 4, pp. 501-504, (1990)
  • [20] Andreoli S.P., Captopril scavenges hydrogen peroxide and reduces, but does not eliminate, oxidant-induced cell injury, Am J Physiol, 264, pp. F120-F127, (1993)